P490: UPDATED SURVIVAL, BLOOD COUNT RECOVERY AND SAFETY RESULTS FROM THE AGILE STUDY IN PATIENTS WITH ACUTE MYELOID LEUKEMIA TREATED WITH IVOSIDENIB + AZACITIDINE COMPARED TO PLACEBO + AZACITIDINE

P490: UPDATED SURVIVAL, BLOOD COUNT RECOVERY AND SAFETY RESULTS FROM THE AGILE STUDY IN PATIENTS WITH ACUTE MYELOID LEUKEMIA TREATED WITH IVOSIDENIB + AZACITIDINE COMPARED TO PLACEBO + AZACITIDINE

Bibliographic Details
Main Authors:	Hartmut Döhner, Pau Montesinos, Susana Vives Polo, Ewa Zarzycka, Jianxiang Wang, Marta Riva, Michael Heuser, Rodrigo Calado, Andre Schuh, Su-Peng Yeh, Jianan Hui, Diego Gianolio, Prapti A Patel, Christian Recher, Stephane de Botton
Format:	Article
Language:	English
Published:	Wiley 2023-08-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000968868.83152.da

Similar Items

P557: HEMATOLOGIC IMPROVEMENTS WITH IVOSIDENIB + AZACITIDINE COMPARED WITH PLACEBO + AZACITIDINE IN PATIENTS WITH NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA
by: H. Dohner, et al.
Published: (2022-06-01)

P556: CHANGES IN HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA RECEIVING IVOSIDENIB + AZACITIDINE OR PLACEBO + AZACITIDINE
by: A. Schuh, et al.
Published: (2022-06-01)

P430: MOLECULAR CHARACTERIZATION OF CLINICAL RESPONSE IN NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA PATIENTS TREATED WITH IVOSIDENIB + AZACITIDINE COMPARED TO PLACEBO + AZACITIDINE
by: S. de Botton, et al.
Published: (2022-06-01)

The AGILE trial of ivosidenib plus azacitidine versus azacitidine alone: How many limitations is too many?
by: Anjali Bhatt, et al.
Published: (2022-11-01)

Mutant isocitrate dehydrogenase 1 inhibitor ivosidenib in combination with azacitidine for newly diagnosed acute myeloid leukemia
by: DiNardo, CD, et al.
Published: (2020)

A phase Ib/II study of ivosidenib with venetoclax +/- azacitidine in IDH1-mutated hematologic malignancies
by: Lachowiez, CA, et al.
Published: (2022)

A phase Ib/II study of ivosidenib with venetoclax ± azacitidine in IDH1-mutated myeloid malignancies
by: Lachowiez, CA, et al.
Published: (2023)

A phase Ib/II study of ivosidenib with venetoclax plus /- azacitidine in IDH1-mutated myeloid malignancies
by: Lachowiez, CA, et al.
Published: (2021)

AML-348 A phase Ib/II study of ivosidenib with venetoclax +/- azacitidine in IDH1-mutated hematologic malignancies
by: Lachowiez, C, et al.
Published: (2022)

Safety and Clinical Activity of Mutant IDH1 Inhibitor IVOSIDENIB (IVO; AG-120) In Combination with AZACITIDINE (AZA) for Newly Diagnosed Acute Myeloid Leukemia (ND AML)
by: DiNardo, C, et al.
Published: (2019)

Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial
by: DiNardo, CD, et al.
Published: (2021)

Safety and efficacy of azacitidine in myelodysplastic syndromes
by: Carlos E Vigil, et al.
Published: (2010-09-01)

Magrolimab + azacitidine versus azacitidine + placebo in untreated higher risk myelodysplastic syndrome: the Phase 3, randomized, ENHANCE Study
by: Garcia-Manero, G, et al.
Published: (2021)

The role of azacitidine in the management of myelodysplastic syndromes (MDS)
by: KS G&ouml;tze, et al.
Published: (2009-10-01)

Azacitidine for Front-Line Therapy of Patients with AML: Reproducible Efficacy Established by Direct Comparison of International Phase 3 Trial Data with Registry Data from the Austrian Azacitidine Registry of the AGMT Study Group
by: Lisa Pleyer, et al.
Published: (2017-02-01)

Magrolimab + azacitidine versus azacitidine + placebo in untreated higher risk (HR) myelodysplastic syndromes (MDS): the Phase 3, randomized, ENHANCE Study
by: Garcia-Manero, G, et al.
Published: (2021)

Magrolimab + azacitidine versus azacitidine + placebo in untreated higher risk (HR) myelodysplastic syndrome (MDS): the phase 3, randomized, ENHANCE study
by: Garcia-Manero, G, et al.
Published: (2021)

G-CSF plus azacitidine versus azacitidine alone for patients with high-risk myelodysplastic syndrome: academic, open label, randomized trial
by: Tomáš Stopka, et al.
Published: (2022-07-01)

Impact of TP53 mutations in acute myeloid leukemia patients treated with azacitidine.
by: Pierre Bories, et al.
Published: (2020-01-01)

Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens
by: John F. Seymour, et al.
Published: (2017-12-01)

RELAPSED UBTF-TD MDS TREATED WITH VENETOCLAX AND AZACITIDINE
by: Henrik Hasle, et al.
Published: (2023-12-01)

Outcome of therapy-related myeloid neoplasms treated with azacitidine
by: Fianchi Luana, et al.
Published: (2012-08-01)

PB2005: AZACITIDINE IN COMBINATION WITH 14-DAY VENETOCLAX VERSUS AZACITIDINE MONOTHERAPY FOR MYELODYSPLASTIC SYNDROME WITH INCREASED BLASTS-2 IN CLINICAL PRACTICE SETTING
by: Andrius Žučenka, et al.
Published: (2023-08-01)

EXPLORING THE EFFICACY OF AZACITIDINE AND VENETOCLAX COMBINATION IN TREATING ACUTE MYELOID LEUKEMIA IN CASES OF RELAPSE FOLLOWING AZACITIDINE TREATMENT AND HIGH-DOSE VITAMINS THERAPY
by: VM Sthel, et al.
Published: (2023-10-01)

MDS-197: Magrolimab + azacitidine versus azacitidine + placebo in untreated higher-risk (HR) myelodysplastic syndromes (MDS): the phase 3, randomized, ENHANCE study
by: Garcia-Manero, G, et al.
Published: (2021)

Use of Azacitidine or Decitabine for the Up-Front Setting in Acute Myeloid Leukaemia: A Systematic Review and Meta-Analysis
by: Miriam Saiz-Rodríguez, et al.
Published: (2021-11-01)

CMV Colitis: A Rare Complication of Azacitidine and Venetoclax Chemotherapy
by: Mustafa Nissar Bankur, et al.
Published: (2022-06-01)

Refinement of prognosis and the effect of azacitidine in intermediate-risk myelodysplastic syndromes
by: Konstantinos Liapis, et al.
Published: (2021-02-01)

Impact of Skeletal Muscle Depletion on Patients with Myelodysplastic Syndrome Treated with Azacitidine
by: Eri Takada, et al.
Published: (2024-02-01)

Case report: Venetoclax plus Azacitidine in treatment of acute undifferentiated leukemia
by: Yu Cui, et al.
Published: (2024-12-01)

5-AZACITIDINE IN HIGH RISK MYELODYSPLASTIC SYNDROME-SINGLE CENTER EXPERIENCE
by: I. Mandac Smoljanovic, et al.
Published: (2024-01-01)

Azacitidine induced lung injury: report and contemporary discussion on diagnosis and management
by: Ruah Alyamany, et al.
Published: (2024-02-01)

A Novel Regimen for Treating Melanoma: MCL1 Inhibitors and Azacitidine
by: Chiara R. Dart, et al.
Published: (2021-07-01)

MYELODYSPLASTIC SYNDROME RESPONDING TO THE AZACITIDINE PROTOCOL ASSOCIATED WITH HIGH DOSES OF VITAMINS
by: VM Sthel, et al.
Published: (2023-10-01)

Venetoclax with decitabine or azacitidine in the first‐line treatment of acute myeloid leukemia
by: Ian M. Bouligny, et al.
Published: (2023-05-01)

An unusual response to 5‐azacitidine by a patient with chronic myelomonocytic leukemia
by: Anwarul Islam
Published: (2023-08-01)

Sweet Syndrome in a Patient with Acute Leukemia on Azacitidine and Venetoclax Treatment
by: Rezmuves Maria Gabriela, et al.
Published: (2023-09-01)

A Case of Organizing Pneumonia Following Azacitidine Treatment for Myelodysplastic Syndrome
by: Kelly Ann Hutchinson, et al.
Published: (2023-05-01)

Late-onset Erythropoietic Protoporphyria Associated with Myelodysplastic Syndrome Treated with Azacitidine
by: Ai Yoshioka, et al.
Published: (2017-11-01)

A Case of Leukemia Cutis with Acute Myeloid Leukemia on Azacitidine Therapy
by: Asude Kara, et al.
Published: (2017-05-01)